Curcumin blocks specific enzyme in cancers like multiple myeloma and TNBC

Researchers from San Diego have shown(1) that curcumin is a highly potent and selective inhibitor of Dual-specificity tyrosine-regulated Kinase 2 (DYRK2), which in turn regulates the 26S proteasome. By disturbing the proteasome activity they found cell proliferation reduced greatly and the cancer load declined.

Proteasome-addicted cancers include Triple Negative Breast Cancer and Multiple Myeloma.

Curcumin comprises just 3% of the root Turmeric (curcuma longa) and has long been used as an antioxidant and microbe killer. On this website we have provided Clinical Trial data that shows it can make certain drugs work better while protecting healthy cells during chemotherapy.

Jack E. Dixon, Ph.D., Professor of Pharmacology, Cellular and Molecular Medicine, Chemistry and Biochemistry at UC San Diego, commented, “Our results reveal an unexpected role of curcumin’.

Chris Woollams, former Oxford University Biochemist and founder of CANCERactive said, ”We always advocate curcumin for Multiple Myeloma and TNBC, and have provided research for readers previously. It is always good when someone works out how it works, though. The standard dose for us is between 1.0 and 3.2 gm. A good number of people with Myeloma in America take 3.2 gm. You should always take it with black pepper and a little olive oil. We have had a couple of patients go to 8 gm with dramatic and positive results though!”

Go to: Triple Negative Breast Cancer overview

Ref